CureusSep 25, 2026

Unintentional Limited Use of Incretin Treatment in Diabetes with Kidney Disease: Need for Careful Distribution

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗

Updated Sep 26, 2026

Abstract

Glucagon-like peptide-1 (GLP-1) receptor agonists have shown strong renal outcomes in patients with type 2 diabetes and chronic kidney disease (CKD).

A large randomized trial was stopped early due to the observed benefits of GLP-1 receptor agonists in CKD patients.
Access to these medications is often limited for patients most in need, driven by market dynamics focused on weight loss rather than nephrologic risk.
Cost-effectiveness analyses indicate that these agents exceed accepted value thresholds at list price.
The current allocation of these treatments reflects a rationing by default rather than a policy-based decision.
There is an obligation for nephrology to advocate for access based on clinical need rather than financial capability.

Simplified

Glucagon-like peptide-1 (GLP-1) receptor agonists have produced strong renal outcome data in patients with type 2 diabetes and chronic kidney disease (CKD), including a large randomized trial stopped early for benefit. Yet the patients with the best claim to these drugs are often the ones least able to obtain them. Supply and price are driven less by nephrologic risk than by a consumer market organized around elective weight loss, direct-to-consumer telehealth, and, until recently, a large compounding economy; at list price, cost-effectiveness analyses place these agents well above accepted value thresholds. This editorial argues that the resulting pattern of access amounts to rationing by default rather than by policy, and that nephrology has an obligation to name it and to press for allocation guided by clinical need. Whether these agents work in CKD is settled. The open question is who receives them once ability to pay, rather than risk of kidney failure, sets the order of the line. When access is constrained, we argue, priority should follow indication and kidney risk rather than purchasing power.